2020
DOI: 10.1159/000510673
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness of Oral Tofacitinib Dose Tapering in a Case of Alopecia Areata Universalis

Abstract: Introduction: Alopecia areata (AA) is a form of nonscarring alopecia and one of the most common autoimmune disorders. Persistent or severe variants lead to potential disfigurement and are associated with a significant negative impact on the patient’s quality of life. Case Presentation: A 51-year-old female patient presenting with refractory alopecia universalis was successfully treated with oral tofacitinib. Recurrence was not observed following 17 months of therapy. Discussion/Conclusion: None of the currentl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(8 citation statements)
references
References 15 publications
(61 reference statements)
0
7
0
Order By: Relevance
“…A total of 37 studies matched the inclusion criteria and were included in this study ( 18 54 ). Twenty-two studies originated from North America ( 18 22 , 26 , 27 , 29 , 31 , 35 , 37 , 41 , 42 , 44 48 , 50 , 51 , 53 , 54 ), 11 studies from Asia ( 28 , 32 34 , 36 , 38 40 , 43 , 49 , 52 ), 3 studies from Australia ( 24 , 25 , 30 ) and 1 study from Europe ( 23 ). The included original articles were 7 randomized trials ( 19 22 , 26 , 27 , 33 ), 5 non-randomized trials ( 25 , 42 , 44 , 53 , 54 ), 4 retrospective ( 28 , 39 , 43 , 51 ) and 21 case-series ( 18 , 23 , 24 , 29 32 , 34 38 , 40 , 41 , 45 50 , 52 ).…”
Section: Resultsmentioning
confidence: 99%
“…A total of 37 studies matched the inclusion criteria and were included in this study ( 18 54 ). Twenty-two studies originated from North America ( 18 22 , 26 , 27 , 29 , 31 , 35 , 37 , 41 , 42 , 44 48 , 50 , 51 , 53 , 54 ), 11 studies from Asia ( 28 , 32 34 , 36 , 38 40 , 43 , 49 , 52 ), 3 studies from Australia ( 24 , 25 , 30 ) and 1 study from Europe ( 23 ). The included original articles were 7 randomized trials ( 19 22 , 26 , 27 , 33 ), 5 non-randomized trials ( 25 , 42 , 44 , 53 , 54 ), 4 retrospective ( 28 , 39 , 43 , 51 ) and 21 case-series ( 18 , 23 , 24 , 29 32 , 34 38 , 40 , 41 , 45 50 , 52 ).…”
Section: Resultsmentioning
confidence: 99%
“…In this study, as in the most studies, cases treated with a dosage of 5 mg twice a day of tofacitinib were followed after 6 month 18,28,29 . The average maintenance dose of the drug in our study was 7 mg daily, which reduced the risk of any side effects caused by increasing the dose of the drug.…”
Section: Discussionmentioning
confidence: 84%
“…In this study, as in the most studies, cases treated with a dosage of 5 mg twice a day of tofacitinib were followed after 6 month. 18,28,29 The average maintenance dose of the drug in our study was 7 mg daily, which reduced the risk of any side effects caused by increasing the dose of the drug. In studies conducted by Steves et al 29 and Ibrahim et al, 18 10 mg of tofacitinib was prescribed after 4-5 months follow-up for treatment stability.…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…21 This is one of the main shortcomings of these agents. Thus, maintenance therapy 13,22 or taper dose 23 after remission have been proposed. We adopted this approach as we found the maintenance therapy proved to be effective to prevent the recurrence of hair loss with minimal adverse events in our cohort.…”
Section: Resultsmentioning
confidence: 99%